project (a national surveillance system of such events). The objective of the project is to determine the annual number and temporal trends of SAEs associated with any treatment for LTBI in the United States. Surveillance of such events will provide data to support periodic evaluation or potential revision of guidelines for treatment of persons with LTBI.

On December 9, 2011, CDC published the Recommendations for Use of an Isoniazid-Rifapentine Regimen with Direct Observation to Treat Latent Mycobacterium tuberculosis Infection in MMWR 2011;60(48);1650–1653. Isoniazid-Rifapentin (3HP) is a new biweekly 3-month treatment regimen for LTBI. Since 2011, there have been 28 reports of SAE; 26 of these were associated with 3HP.

The CDC requests approval for a 3year extension of the previously approved National Surveillance for Severe Adverse Events Associated with Treatment of Latent Tuberculosis Infection. This project will continue the passive reporting system for SAEs associated with therapy for LTBI. The system will rely on medical chart review and/or onsite investigations by TB control staff.

Potential respondents are any of the 60 reporting areas for the national TB surveillance system (the 50 states, the District of Columbia, New York City, Puerto Rico, and 7 jurisdictions in the Pacific and Caribbean).

Data will be collected using the data collection form for SAEs associated with LTBI treatment. Based on previous reporting, CDC anticipates receiving an average of 10 responses per year from the 60 reporting areas. The data collection form is completed by healthcare providers and health departments for each reported hospitalization or death related to treatment of LTBI and contains demographic, clinical, and laboratory information.

CDC will analyze and periodically publish reports summarizing national LTBI treatment adverse events statistics and also will conduct special analyses for publication in peer-reviewed scientific journals to further describe and interpret these data.

The Food and Drug Administration (FDA) collects data on adverse events related to drugs through the MedWatch: The FDA Medical Products Reporting Program (OMB#0910–0291, exp. 6/30/2015). CDC is encouraging health departments and healthcare providers to report SAEs to FDA. Reporting will be conducted through telephone, email, or during CDC site visits.

CDC is requesting approval for approximately 60 burden hours annually. The only cost to respondents is time to gather medical records and time to complete the reporting form. There are no costs to respondents other than their time.

#### ESTIMATED ANNUALIZED BURDEN HOURS

| Type of respondent | Form name | Number of respondents | Number of responses per respondent | Average<br>burden per<br>response<br>(in hours) |
|--------------------|-----------|-----------------------|------------------------------------|---|
| Physician          | NSSAE     | 10                    | 1                                  | 1   |
| Nurse              | NSSAE     | 10                    | 1                                  | 4   |
| Medical Clerk      | NSSAE     | 10                    | 1                                  | 1   |

#### Lerov A. Richardson,

Chief, Information Collection Review Office, Office of Scientific Integrity, Office of the Associate Director for Science, Office of the Director, Centers for Disease Control and Prevention.

[FR Doc. 2014–25250 Filed 10–22–14; 8:45 am] BILLING CODE 4163–18–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

Notice of Intent To Award Ebola Response Outbreak Funding to African Field Epidemiology Network (AFENET)

**AGENCY:** Centers for Disease Control and Prevention (CDC), Department of Health and Human Services (HHS).

**ACTION:** Notice.

**SUMMARY:** This notice provides public announcement of CDC's intent to award Ebola appropriations to AFENET for response to the Ebola outbreak funding. This award was proposed in Fiscal Year (FY) 2015 under funding opportunity announcement GH10–1006

Strengthening the Development of Applied Epidemiology and Sustainable Public Health Capacity through Collaboration, Program Development and Implementation, Communication and Information Sharing."

Catalogue of Federal Domestic Assistance Number (CFDA): 93.283

**Authority:** Public Health Service Act 42 U.S.C. 287b 31 U.S.C. 6305 42 CFR 63a.

Single award may be awarded totaling \$1,800,000 for Ebola response outbreak.

Funding is appropriated under the Continuing Appropriations Resolution, 2015, Public Law 113–164, 128 Stat. 1867 (2014).

**DATES:** Anticipated award date 10/30/2014 through 09/14/2015

Application Due Date: 10/23/2014 Project Number is CDC-RFA-GH10-1006

ADDRESSES: CDC has waived the Grants.gov electronic submission process for this requirement. Recipients are hereby authorized to submit a paper copy application for (CDC–RFA–GH10–1006) via Express Mail (i.e. FedEx, UPS, or DHL) and send the application via email. Mailed applications must be

address to Arthur C. Lusby, Centers for Disease Control and Prevention, 2920 Brandywine Road, Atlanta, GA 30341, telephone (770) 488–2865, or email him at ALusby@cdc.gov. The application must include a detailed line-item budget and justification to support the Ebola activities from October 31, 2014 to September 29, 2015. Please download the following to complete the application package: http:// apply07.grants.gov/apply/forms/ sample/SF424 2 1-V2.1.pdf-Application Package; http:// www.cdc.gov/od/pgo/funding/docs/ CertificationsForm.pdf—Certifications; http://www.cdc.gov/od/pgo/funding/ grants/Budget Preparation Guidelines 8-2-12.docx—CDC-PGO Budget Guidelines; http://apply07.grants.gov/ apply/forms/sample/SF424A-V1.0.pdf— SF-424A Budget Information.

All applications must be submitted to and received by the Grants Management Officer (GMO) no later than 11:59 p.m. EST on October 23, 2014 and please provide the GMO a PDF version of the application by email to the following email address: pgoebolaresponse@cdc.gov subject line: CDC-RFA-GH10-

1006.

Applicants will be provided with the Funding Opportunity Announcement (FOA) and additional application submission guidance via email notification. Applicants may contact the POCs listed with questions regarding the application process.

#### FOR FURTHER INFORMATION CONTACT:

# For Programmatic or Technical Assistance

Kenneth Johnson, Project Officer, Department of Health and Human Services, Centers for Disease Control and Prevention, 1600 Clifton Rd MS E– 93, Atlanta, GA 30333, Telephone: 404 639–4203, KAJO@cdc.gov.

For financial, awards management, or budget assistance: Arthur C. Lusby, Grants Management Officer, Centers for Disease Control and Prevention, 2920 Brandywine Road, Atlanta, GA 30341, Telephone (770) 488–2865, Email: ALusby@cdc.gov.

SUPPLEMENTARY INFORMATION: The purpose of this notice is to solicit an application from AFENET to assist in addressing the spread of the Ebola virus in West Africa and contain the disease as quickly as possible. The funding will support the impacted Ebola-affected countries and the surrounding countries to combat this health crisis. This funding will target the following countries: Liberia, Sierra Leone, Guinea, Burkina Faso, Niger, Mauritania, Mali, Senegal, Guinea Bissau, Ghana, Gambia, Cote d'Ivoire, Togo, Benin, and Nigeria to support the response to the outbreak of Ebola virus in West Africa. This funding will enable the U.S. to provide unified mobilization to address a crisis of this magnitude. CDC will continue to build partnerships and strengthen existing projects to respond to Ebola. CDC and its partners will help to address the need for surveillance, detection, coordination, response, and increase eligible governments' capacity to respond to the Ebola outbreak.

#### **Award Information**

Type of Award: Expansion Supplement.

Approximate Total Current Fiscal Year ACA Funding: \$1,800,000.

Anticipated Number of Awards: single.

Fiscal Year Funds: 2015.

Anticipated Award Date: October 30, 2014.

Application Selection Process: Funding will be awarded to applicant based on results from the technical review recommendation. Dated: October 20, 2014.

#### Ron A. Otten,

Acting Deputy Associate Director, Centers for Disease Control and Prevention.

[FR Doc. 2014–25248 Filed 10–20–14; 4:15 pm] BILLING CODE 4163–18–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

# Office of the Director; The Advisory Committee to the Director, CDC; Meeting

Notice of Cancellation: This notice was published in the **Federal Register** on September 29, 2014, Volume 79, Number 189, page 58353. The meeting previously scheduled to convene on October 23, 2014 has been cancelled.

Contact Person for More Information: Gayle Hickman, Committee Management Specialist, Office of the Chief of Staff, 1600 Clifton Road, Mail Stop D–14, Atlanta, GA 30303; telephone 404/639–7158, fax 404/639–7212; Email: ghickman@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign **Federal Register** notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

#### Claudette Grant,

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

[FR Doc. 2014–25258 Filed 10–22–14; 8:45 am] BILLING CODE 4163–18–P

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

# Centers for Disease Control and Prevention

Board of Scientific Counselors, Office of Public Health Preparedness and Response, Board of Scientific Counselors (BSC, OPHPR); Notice of Meeting Cancellation

Cancellation: This notice was published in the **Federal Register** on September 23, 2014, Volume 79, Number 184, page 56806. The meeting previously scheduled to convene on October 27–28, 2014, has been cancelled.

Contact Person for More Information: Christye Brown, BSC Coordinator, Office of Science and Public Health Practice, Centers for Disease Control and Prevention, 1600 Clifton Road NE., Mailstop D–44, Atlanta, Georgia 30333, Telephone: (404) 639–7957; Facsimile: (404) 639–7977; Email: OPHPR.BSC.Ouestions@cdc.gov.

The Director, Management Analysis and Services Office, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry.

#### Claudette Grant.

Acting Director, Management Analysis and Services Office, Centers for Disease Control and Prevention.

# DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Administration for Children and Families

#### Child Support Enforcement Program; Report to Congress

**AGENCY:** Administration for Children and Families, Department of Health and Human Services (HHS).

**ACTION:** Notice of request for information.

**SUMMARY:** The Department of Health and Human Services, Administration for Children and Families, Office of Child Support Enforcement requests public comments to inform its upcoming Report to Congress. The Report to Congress ("Report") is required to be submitted no later than June 30, 2015 under Title III, Section 305 of H.R. 4980 (Pub. L. 113–183), Preventing Sex Trafficking and Strengthening Families Act of 2014. The legislation was signed into law on September 29, 2014. This Request for Information offers the opportunity for interested individuals and organizations to provide input on specific Report requirements or other information that would be valuable to the Report development.

**DATES:** Comments must be received by 11:59 p.m. on December 22, 2014, to be considered.

**ADDRESSES:** Respondents are encouraged to submit their comments through the following methods; although email is the preferred method of submission.

Email: Email comments concerning this notice to OCSEreport@acf.hhs.gov. Email submissions will receive an electronic confirmation acknowledging